During the last session, RAPT Therapeutics Inc (NASDAQ:RAPT)’s traded shares were 0.5 million, with the beta value of the company hitting 0.09. At the end of the trading day, the stock’s price was $1.08, reflecting an intraday gain of 2.86% or $0.03. The 52-week high for the RAPT share is $27.35, that puts it down -2432.41 from that peak though still a striking 7.41% gain since the share price plummeted to a 52-week low of $1.00. The company’s market capitalization is $37.76M, and the average intraday trading volume over the past 10 days was 1.72 million shares, and the average trade volume was 511.35K shares over the past three months.
RAPT Therapeutics Inc (RAPT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.00. RAPT has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.39.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RAPT Therapeutics Inc (NASDAQ:RAPT) trade information
RAPT Therapeutics Inc (RAPT) registered a 2.86% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.86% in intraday trading to $1.08, hitting a weekly high. The stock’s 5-day price performance is -2.26%, and it has moved by -38.98% in 30 days. Based on these gigs, the overall price performance for the year is -92.09%. The short interest in RAPT Therapeutics Inc (NASDAQ:RAPT) is 2.67 million shares and it means that shorts have 9.95 day(s) to cover.
The consensus price target of analysts on Wall Street is $33, which implies an increase of 96.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $55 respectively. As a result, RAPT is trading at a discount of -4992.59% off the target high and -85.19% off the low.
RAPT Therapeutics Inc (RAPT) estimates and forecasts
Statistics show that RAPT Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. RAPT Therapeutics Inc (RAPT) shares have gone down -74.16% during the last six months, with a year-to-date growth rate less than the industry average at 8.20% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 51.91% this quarter and then jump 34.81% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -12.39%. While earnings are projected to return 18.09% in 2024.
RAPT Dividends
RAPT Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
RAPT Therapeutics Inc (NASDAQ:RAPT)’s Major holders
RAPT Therapeutics Inc insiders own 1.84% of total outstanding shares while institutional holders control 86.65%, with the float percentage being 88.27%. FMR LLC is the largest shareholder of the company, while 144.0 institutions own stock in it. As of 2024-06-30, the company held over 5.24 million shares (or 13.5546% of all shares), a total value of $15.97 million in shares.
The next largest institutional holding, with 3.11 million shares, is of VANGUARD GROUP INC’s that is approximately 8.0472% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $9.48 million.
Also, the Mutual Funds coming in first place with the largest holdings of RAPT Therapeutics Inc (RAPT) shares are Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Fidelity Growth Company Fund owns about 1.52 shares. This amounts to just over 4.34 percent of the company’s overall shares, with a $1.64 million market value. The same data shows that the other fund manager holds slightly less at 1.12, or about 3.21% of the stock, which is worth about $1.21 million.
